Krystal Biotech, Inc.
KRYS
$143.96
-$2.34-1.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.65% | 94.88% | 116.26% | 879.91% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.65% | 94.88% | 116.26% | 879.91% | -- |
| Cost of Revenue | 19.24% | 107.85% | 72.38% | 2,897.31% | -- |
| Gross Profit | 38.28% | 94.15% | 119.47% | 825.92% | -- |
| SG&A Expenses | 27.27% | 25.58% | 26.34% | 21.17% | 6.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.27% | 31.88% | 27.57% | 41.56% | 29.36% |
| Operating Income | 86.59% | 522.03% | 1,218.64% | 234.39% | 155.37% |
| Income Before Tax | 191.52% | 4,577.79% | 356.13% | -63.13% | 148.31% |
| Income Tax Expenses | 1,669.81% | -- | 59.34% | -- | -- |
| Earnings from Continuing Operations | 146.23% | 3,734.01% | 423.23% | -66.34% | 146.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.23% | 3,734.01% | 423.23% | -66.34% | 146.88% |
| EBIT | 86.59% | 522.03% | 1,218.64% | 234.39% | 155.37% |
| EBITDA | 77.13% | 474.37% | 934.35% | 239.70% | 160.68% |
| EPS Basic | 143.55% | 3,669.30% | 412.51% | -67.13% | 143.70% |
| Normalized Basic EPS | 62.10% | 218.71% | 346.77% | 314.40% | 180.12% |
| EPS Diluted | 143.40% | 3,900.00% | 409.41% | -67.38% | 142.40% |
| Normalized Diluted EPS | 63.24% | 218.28% | 339.94% | 312.12% | 177.32% |
| Average Basic Shares Outstanding | 1.09% | 1.84% | 2.08% | 2.40% | 7.28% |
| Average Diluted Shares Outstanding | 0.38% | 1.98% | 3.70% | 3.50% | 11.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |